Janssen sees USD 12bn sales potential in Genmab-developed drugs
Three potential candidates from Genmab have a USD 4bn top sales potential each, says Head of the Global Oncology Therapeutic Area at Janssen Peter Lebowitz.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Genmab is already bringing in most of its top line revenue from partner Johnson & Johnson's sales of Darzalex, which is a Genmab-developed drug, but revenue streams from Johnson & Johnson's pharmaceutical arm could be considerably increased in the future, reports Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
Genmab upgrades financial guidance again
For subscribers
.jpg)
.jpg&w=384&q=75)
